The effect of a novel glycoprotein IIb/IIIa antagonist, SR 121566A, on platelet aggregation and activation in rhesus monkeys

Clinical and Applied Thrombosis/Hemostasis

Volumn 7, Issue 1, 2001, Pages 10-15

  Santillan, Mark Kharim Orcullo ^a   Herring, Justin ^a   Hoppensteadt, Debra A ^a   Jeske, Walter ^a   Herbert, Jean Marc ^b   Fareed, Jawed ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b SANOFI   (France)

Author keywords

Antiplatelet; Flow cytometry; Glycoprotein IIb IIIa; Pharmacokinetics; Platelet aggregation; Primates

Indexed keywords

3 [[4 [4 (AMINOIMINOMETHYL)PHENYL] 2 THIAZOLYL](1 CARBOXYMETHYL 4 PIPERIDINYL)AMINO]PROPIONIC ACID; ADENOSINE DIPHOSPHATE; FIBRINOGEN RECEPTOR ANTAGONIST; PADGEM PROTEIN; THROMBIN RECEPTOR ACTIVATING PEPTIDE;

ANIMAL EXPERIMENT; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; DRUG EFFECT; FLOW CYTOMETRY; MALE; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION;

ADENOSINE DIPHOSPHATE; ANIMALS; BENZYLAMINES; DRUG ADMINISTRATION ROUTES; DRUG EVALUATION, PRECLINICAL; MACACA MULATTA; MALE; P-SELECTIN; PIPERIDINES; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; THIAZOLES; TIME FACTORS;

EID: 0035140978     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602960100700103     Document Type: Article

References (24)

1. Arginyl-glycyl-aspartic acid sequences and fibrinogen binding to platelets
2. The tetrapeptide analogue of the cell attachment site of fibronectin inhibits platelet aggregation and fibrinogen binding to activated platelets
3. The platelet membrane glycoprotein IIb-IIIa complex
4. The effect of Arg-Gly-Asp-containing peptides on fibrinogen and von Willenbrand factor binding to platelets
5. Glycoprotein IIb-IIIa Antagonists
6. The human platelet fibrinogen receptor: Clinical and therapeutic significance
7. Trends Pharmacol Sci
8. Collaborative overview of randomized trials of antiplatelet therapy - I: Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients
9. Platelet glycoprotein IIb/IIIa receptor antagonists in coronary artery disease
10. Inhibitors of platelet glycoprotein IIb/IIIa receptors. Will they be useful when given chronically?
11. Randomized trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: Results at six months
12. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty: The EPIC Investigation
13. Low molecular weight fibrinogen receptor antagonists
14. Antithrombotic agents: From RGD to peptidemimetics
15. Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina: The Canadian Lamifiban Study
16. Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty
17. The IMPACT Investigators. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention
18. Antiplatelet and antithrombotic efficacy of SR 121787, a nonpeptide orally active GP IIb/IIIa antagonist in rabbits: A comparison with clopidogrel and aspirin
19. Effect of SR 121566A, a potent GP IIb-IIIa antagonist on platelet-mediated thrombin generation in vitro and in vivo
20. Effect of glycoprotein IIb/IIIa antagonists on the HIT serum induced activation of platelets
21. Effect of Sr 121566A a potent GP IIb/IIIa antagonist, on the HIT serum/heparin-induced platelet mediated activation of human endothelial cells
22. Antithrombotic effects of TAK-029, a novel GP IIb/IIIa antagonist, in guinea pigs: Comparative studies with ticlopidine, clopidogrel, aspirin, prostaglandin El, and argatroban
23. Novel nonpeptide anti-platelet glycoprotein IIb/IIIa receptor antagonist, DMP754: Receptor binding affinity and specificity
24. Pharmacokinetics, pharmacodynamics and tolerability of a potent, non-peptidic, GP IIb/IIIa receptor antagonist following multiple oral administrations of a prodrug form